BCM
RETA

Bluefin Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bluefin Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,703
Closed -$823K – 500
2020
Q1 		$823K Buy
+5,703
New +$1.1M 0.11% 138

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bluefin Capital Management's RETA Position: Q2 2020 in Review

Bluefin Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 5,703 shares — an estimated $823K sold.

Bluefin Capital Management first reported a position in RETA in Q1 2020 and held it in 1 quarter. The position peaked at $823K in Q1 2020. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

  • Bluefin Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 5,703 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $823K.
  • Bluefin Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 1 quarter.
  • Bluefin Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $823K in Q1 2020.
  • 207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Bluefin Capital Management's 13F filing for Q2 2020, filed 17 Aug 2020.